所有图片(1)
About This Item
经验公式（希尔记法）:
C10H12N4O3
CAS号:
分子量:
236.23
Beilstein:
3619529
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
didanosine
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
OC[C@@H]1CC[C@@H](O1)n2cnc3C(=O)NC=Nc23
InChI
1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
InChI key
BXZVVICBKDXVGW-NKWVEPMBSA-N
正在寻找类似产品? 访问 产品对比指南
相关类别
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Didanosine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Patricia Pecora Fulco et al.
The Annals of pharmacotherapy, 37(9), 1325-1328 (2003-08-19)
To evaluate the pharmacokinetic interaction between tenofovir and didanosine when used in combination as a highly active antiretroviral therapy regimen. Literature retrieval was accessed through MEDLINE (1966-January 2003) using the terms tenofovir and didanosine. Abstracts from recent meetings, including the
M Youle
Antiviral therapy, 3 Suppl 4, 35-37 (2000-03-21)
The current focus on simplifying treatment regimens for patients with human immunodeficiency virus (HIV) infection has contributed to the interest in once-daily therapy. The triphosphate of didanosine (2',3'-dideoxyinosine or DDI) has a long intracellular half-life, which supports the use of
Masahiko Okiyama et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 120(2), 115-122 (2002-08-22)
An active metabolite, ddATP, of didanosine that is an analogue of purine-nucleoside (a component of nucleic acid) was known to inhibit the activity of DNA polymerase for E. coli. In 1985, Dr. Michiya et al. of NCI reported that didanosine
Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
M Masiá et al.
International journal of STD & AIDS, 16(9), 646-648 (2005-09-24)
The combination of tenofovir and didanosine results in an increase in the didanosine plasma exposure and might augment the risk for didanosine toxicity. Although pharmacokinetic studies support a didanosine dose reduction to 250 mg when used concurrently with tenofovir in
C M Perry et al.
Drugs, 52(6), 928-962 (1996-12-01)
Didanosine is a dideoxynucleoside analogue, which is phosphorylated to the active metabolite dideoxyadenosine triphosphate (ddATP) intracellularly. At therapeutic concentrations, ddATP inhibits HIV replication by inhibiting HIV reverse transcriptase. Didanosine is established as a first-line treatment for patients with HIV disease
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门